Efficacy and safety of ibandronat tablets for treatment of postmenopausal osteoporosis
https://doi.org/10.14412/1995-4484-2005-41
Abstract
Objective. To study efficacy and safety of ibandronat, highly active nitric-containing bisphosphonat in 3-year treatment of pts with postmenopausal osteoporosis using different doses and schemes of treatment. Material and methods. The study was performed as a part of a multicenter double blind placebo-controlled randomized clinical study (BONE study). 85 female aged 55 to 80 yeare with 5-year or longer duration of postmenopausal period having from one to four vertebral fractures and lumbar bone mineral density (BMD) from - 2,0 to -5,0 SD according to T-count were included. The pts were randomized onto three groups: 1 - placebo, 2 - ibandronat 2,5 mg daily, 3 - ibandronat 20 mg every other day during the 24 days (12 doses) every 3 months. Results. After 3 years of treatment pts of group 2 and 3 showed significant increase of lumbar, femoral neck and total femoral BMD (5,9% and 5,8%, p<0,01, 2,0% and 1,9%, 3,3%(p<0,01 and 2,2% respectively). Ibandronat was well tolerated and its adverse events of were comparable with placebo.
References
1. <div><p>Беневоленская Л.И. Бнсфосфонаты в терапии и профилактике остеопороза. Росс, ревматол., 1998, 2, 2-9</p><p>Беневоленская Л.И. Бнсфосфонаты и остеопорозю. Рук. по остеопорозу (под ред. Проф. Л.И.Беневоленской). БИНОМ, М., 2003, 196-216</p><p>Bauss F., Kling L., Sponer G. Comparison of continuous and ciclical administration of ibandronate on bone mass in ovariec- tomized rats. Bone Miner.Res,, 1996, 11 (suppl. 1), S336</p><p>Bidstrup B., Ise J., Huss H. et al. Total dose, and not dosing frequency, determines treatment response to ibandronate. Osteopor. Int. 2000, ll(supl.l), S26</p><p>Chesnut III C.H., Skag A., Christiansen C. et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J.Bone Miner.Res., 2004, 19, 1241-1249</p><p>Cooper C., Emkey R.D., McDonald R.H. et al. Efficacy and safely of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J.CIin. Endocrinol. Metab., 2003, 88, 4609-15</p><p>Delmas P.D., R.R. Recker, Chesnut HI C.H. el al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteopor. Int., 2004, 15, 792-798</p><p>Lalla S., Hothorn L.A., Hagg N. et al. Lifelong of high doses of ibandronate increases bone mass and maintains bone quality in lumbar vertebrae in rats. Osteopor. Int., 1998, 8, 97-103</p><p>Ravn P., Clemmesen B., Riis B.J., Christiansen C. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone, 1996, 19, 527-533</p><p>Ravn P., Christiansen C., Baumann М.,Clemmesen B. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment : Prediction of bone mass changes during treatment. Bone, 1998, 22, 559-564</p><p>Riis B.J., Ise J., von Stein T. et al. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J.Bone Miner.Res., 2001,16, 1871-1878</p><p>Munbauers R.C., Bauss F., Schenk R. et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J.Bone Miner.Res., 1991,6, 1003-1011</p></div><br />
Review
For citations:
Toroplsova N.V., Benevolenskaya L.L., Nikilinskaya O.A., Demin N.V. Efficacy and safety of ibandronat tablets for treatment of postmenopausal osteoporosis. Rheumatology Science and Practice. 2005;43(5):44-47. (In Russ.) https://doi.org/10.14412/1995-4484-2005-41
Views:
804
Email this article 